Abstract
Microemulsions are ideal carriers for poorly soluble substances. They increase the absorption of drugs with
low bioavailability. Methotrexate (MTX), which is used internally in cancer and psoriasis and has many side effects and
it is less soluble in water and its passage through the skin is problematic due to its high molecular weight. An O/W
microemulsion formulation containing MTX has been developed in order to reduce the side effects of the drug, not to
have a first pass effect on the liver, to increase its bioavailability in topical use and to provide ease of use to patients. The
releasing profiles of the gel formulation, prepared by reducing the fluidity of these formulations by polymers, were
investigated through the nylon membrane. Mostly W/O microemulsion systems are available due to design of
preparations but in this study O/W microemulsions and gel forms containing MTX were designed for topical use.
Innovation side of trials will inspire in vivo studies and clinical studies that may cause less harm to patients
dermatologically and provide optimal effect.
Keywords
Microemulsion O/W hydrogel metotrexate franzcell topical release
References
- Karasulu H.Y, Karabulut B, Göker E, Güneri T, Gabor F. Controlled Release of Methotrexate from W/O Microemulsion and Its In Vitro Antitumor Activity. Drug Deliv.2008; 225- 233.https://doi.org/10.1080/10717540601067760
- Yang F, Kamiya N, Goto M. Transdermal delivery of the antirheumatic agent methotrexate using a solid-in-oil nanocarrier. Eur J Pharm Biopharm.2012; 82:158–63.https://doi.org/10.1016/j.ejpb.2012.05.016
- Chan SLE, Cronstein BN, Molecularaction of methotrexate in inflammatory diseases. Division of Clinical Pharmacology. 2002; Vol 4, No 4.https://doi.org/10.1186/ar419
- Chladek J, Martinkova J, Simkova M, Vaneckova J, Koudelkova V, Nozickova M. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol. 1998; 53: 437- 444.https://doi.org/10.1007/s002280050404
- Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem. 2018; 158:502–516.https://doi.org/10.1016/j.ejmech.2018.09.027
- Weinstein GD, McCullough JL, Olsen E. Topical methotrexate therapy for psoriasis. Arch Dermatol. 1989 ;125(2): 227–230.https://doi.org/10.1001/archderm.1989.01670140079014
- Wohlrab J, Neubert RH, Michael J and Naumann S. Methotrexate for topical application in an extemporaneous preparation. J Dtsch Dermatol Ges. 2015; 13(9): 891–901https://doi.org/10.1111/ddg.12622
- Bjerring P, Beck HI, Zachariae H and Søgaard H. Topical treatment of psoriatic skin with methotrexate cream: a clinical, pharmacokinetic, and histological study. Acta Derm Venereol. 1986;66(6):515–519
- Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposoms for dermal administration of metotrexate. Int.J of Pharmaceutics. 2004; 270: 119-125.https://doi.org/10.1016/j.ijpharm.2003.10.006
- Alverez-Figueroa MJ, Delgado-Charro MB, Blanco J. Passive and iontophoretic transdermal penetration of microemulsion methorexate.Int J Pharm. 2001; 212: 101-107.https://doi.org/10.1016/S0378-5173(00)00599-8
- Ceglie A, Das KP, Lindman B. Microemulsion structure in four-component systems for different surfactants, Colloids Surf. 1987; 28: 29 – 40.https://doi.org/10.1016/0166-6622(87)80164-6
- Baroli B, Lopez-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-Mendez J. Microemulsions for topical delivery of 8-methoxsalen. J Control Release. 2000; 69: 209–218.https://doi.org/10.1016/s0168-3659(00)00309-6
- Yazan Y. Emülsiyon Sistemler; Konrollü Salım Sistemleri Derneği Yayınları. 2002; No.1,137–141 David A. Microemulsions. In: Kreuter J, Colloidal drug delivery systems, drug and the pharmaceutical science, a series of textbooks and monographs. New York: Marcel Dekker; 1994. p.31-65.
- Shaffrali FCG, Colver GB, Messenger AG. Experience with low-dose methotrexate for the treatment of eczema in elderly. J Am Acad Dermatol. 2003; 48: 417-9.https://doi.org/10.1067/mjd.2003.137
- Lopes LB. Overcoming the cutaneous barrier with microemulsions. Pharmaceutics 2014;6(1):52- 77.https://doi.org/10.3390%2Fpharmaceutics6010052
- Trotta M, Gasco MR, Pattarino F. Diffusion of Steroid Hormones from O/W Microemulsions: Influence of the Cosurfactant. Acta Pharm Technol.1990; 36: 226-231
- Lawrence MJ, Rees GD. Microemulsion-based Media as Novel Drug Delivery Systems, Adv Drug Del Rev.2000; 45: 89-121.https://doi.org/10.1016/s0169-409x(00)00103-4
- Hu Q, Lin H, Wang Y, Wang X., Yao J, Fu X, Yu X. Design, optimization and evaluation of a microemulsion-based hydrogel with high malleability for enhanced transdermal delivery of levamisole. Int J Pharm. 2021; 605, 120829.https://doi.org/10.1016/j.ijpharm.2021.120829
- Enxue H, Hailing Li, Xiaokun L, Xunxun W, Kun L, Yong D. Transdermal Delivery of Indirubin-Loaded Microemulsion Gel: Preparation, Characterization and Anti-Psoriatic Activity. Int J Mol Sci. 2022; 23, 3798.https://doi.org/10.3390/ijms23073798
- Rahdar A, Hajinezhad M.R, Nasri S, Beyzai H, Barrani M, Trant J.F. The synthesis of methotrexate-loaded F127 microemulsions and their in vivo toxicity in a rat model. J Mol Liquids. 2020; 313, 113449.https://doi.org/10.1016/j.molliq.2020.113449
- Lu G, Jun H.W. Diffusion studies of methotrexate in Carbopol and Poloxamer gels. Int. J of Pharmaceutics. 1997; 160, 1-9.https://doi.org/10.1016/S0378-5173(97)00187-7
- Sintov A.C, Shapiro L. New microemulsion vehicle facilitate spercutaneous penetration in vitro and cutaneous drug bioavailability in vivo. J Control Release. 2004; 95, 173-183.https://doi.org/10.1016/j.jconrel.2003.11.004 Kreilgaard M. Dermal pharmacokinetics of microemulsion formulations determined by in vitro microdialysis. Pharm Res. 2001; 18: 367-373.https://doi.org/10.1023/a:1011067300397
- Alverez-Figueroa MJ, Blanco J. Transdermal delivery of micoemulsion methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm. 2001; 215: 57-65.https://doi.org/10.1016/s0378- 5173(00)00674-8
- Trotta M, Influence of phase transformation on indomethacin release from microemulsions. J Control Release. 1990; 60: 399-405.https://doi.org/10.1016/s0168-3659(99)00094-2
- Kreilgaard M, Pedersen EJ, Jaroszewski, JW. NMR characterization and transdermal drug delivery potential of microemulsion systems. J Control Release. 2000; 69:,421-433.https://doi.org/10.1016/S0168-3659(00)00325-4
- Tanojo H, Junginger HE. In vivo human skin permeability enhancement by oleic acid: transepidermal water loss and fourier-transform infrared spectroscopy studies. J.Control. Release. 1997; 47: 31- 39.https://doi.org/10.1016/S0168-3659(96)01613-6
- Hadgraft J. Skin, the final frontier. Int J Pharm. 2001; 224: 1-18.https://doi.org/10.1016/s0378-5173(01)00731-1
- Peltola S, Saarinen-Savolainen P, Kiesvaara J, Suhonen TM, Urtti A. Microemulsions for topical delivery of estradiol. Int J Pharmaceutics. 2003; 254: 99-107.https://doi.org/10.1016/s0378-5173(02)00632-4.
- Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutice valuation of an investigation a llipophilic compound. Pharm Res. 1992; 9: 87- 93.https://doi.org/10.1023/a:1018987928936
- Ege MA, Karasulu HY, Güneri T. Triangle Phase Diagram Analysis Software. The 4th International Postgraduate Research Sympsium on Pharmaceutics (IPOSHIP2004) Istanbul
- Türk Farmakopesi(2017) Vol.VI p:4505
Details
| Primary Language | English |
|---|---|
| Subjects | Pharmaceutical Biotechnology |
| Journal Section | Articles |
| Authors | |
| Publication Date | June 27, 2025 |
| Published in Issue | Year 2023 Volume: 27 Issue: 2 |